Be sure to improve your cancer treatment outcomes

August 8, 2022

This article was written by Dr. Omer Rashid, DVM, MSc Parasitology and published in Innovative Veterinary Care Journal.

---

Canine cancer study shows machine learning models trained with different data types yield better clinical outcome prediction.

Heterogeneity is a significant issue when we talk about failed cancer treatments. And that is why precision medicine promises a revolution in cancer therapy.

Studies on cancer heterogeneity have enabled scientists to categorize different tumors into subtypes. Cancer treatments that are tailored according to subtypes are bound to yield better clinical outcomes.

ImpriMed, a veterinary precision medicine company, has used the power of AI and machine learning to pinpoint drugs that can be the most effective against particular cancer subtypes in individual patients. A study published in a top veterinary journal showed that ImpriMed’s novel AI training method resulted in improved drug response prediction.

The cancer study objective

The goal of the study was to gauge the effectiveness of a proposed methodology for predicting the likelihood of clinical remission and progression-free survival in individual patients following treatment. Three different types of data were used to train machine learning models in the study. The data included live cancer cell drug sensitivity, immunophenotype, and patient information.

How the study was conducted

A total of 242 dogs suffering from canine lymphoma were selected from a pool of diseased animals. The selected canines were given chemotherapy by board-certified veterinary oncologists. Patients who received at least three of the five drugs that comprise L-(CHOP) chemotherapy were screened within the first four weeks of diagnosis. A subset was then chosen that had data on drug sensitivity, immunophenotype, patient information, and a prognosis of the first 12 weeks after the administration of chemotherapy.

The categorical data obtained were converted into numerical values and rescaled. The compiled data was then used to develop three machine learning models. For each model, the data was split into a train set and test set. The outputs of ML models (classifiers) were the probabilities of achieving clinical remission by the 4th, 8th, or 12th week since the administration of chemotherapy.

The progression-free survival over time for each patient was predicted using the Cox proportional hazard model.

Finally, the performance of the three machine learning models was assessed.

What were the results

The predictive accuracy of the machine learning models was significantly improved by utilizing features from the three different types of data. Superior performance and utility in predicting survival were also observed when compared to the conventional stratification method. It became evident that this novel training methodology can help to improve and personalize cancer care.

What is the inference for veterinarians

The likelihood of clinical remission at various time points with different cancer drugs can aid in making informed treatment decisions. The individualized progression-free survival prospects will also facilitate better preparation for monitoring prognosis and planning follow-up visits after chemotherapy is completed.

ImpriMed’s technology should be an integral part of your lymphoma and leukemia cancer treatment. ImpriMed’s AI-based cancer treatment solution improves clinical outcomes while saving time and money.

www.ImpriMedicine.com

In the News

How Artificial Intelligence Is Revolutionising Cancer Care for Pets

Pets Magazine
Learn More →

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

American Animal Hospital Association NEWStat®
Learn More →

Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

Veterinary Practice
Learn More →

Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

DVM360
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

USA Today
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News
Learn More →

Early leukemia and lymphoma remissions in cats and dogs

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

Novel veterinary oncologic treatments and diagnostics

dvm360
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →